Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder

Small Pharma, a neuropharmaceutical company focused on psychedelic-assisted therapies today confirms, following positive discussions with the U.S. Food and Drug Administration, that preparations are now underway for the U.S. component of its Phase IIb clinical trial for its lead candidate, SPL026, a N,N-dimethyltryptamine assisted therapy for the treatment of major depressive disorder.